TY - JOUR T1 - LATE-BREAKING ABSTRACT: 2-years follow-up (FU) results of ORCADES study: Long-term mandibular repositioning device (MRD) therapy in patients treated for obstructive sleep apnea (OSA) JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA2393 VL - 48 IS - suppl 60 SP - PA2393 AU - Valérie Attali AU - Jean-Marc Collet AU - Marie-Pia d'Ortho AU - Frédéric Goutorbe AU - Jean-Baptiste Kerbrat AU - Hauria Khemliche AU - Damien Leger AU - Lionel Lerousseau AU - Francis Martin AU - Christelle Monaca AU - Pierre-Jean Monteyrol AU - Laurent Morin AU - Eric Mullens AU - Bernard Pigearias AU - Jean-Claude Meurice AU - Marie-Françoise Vecchierini Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA2393.abstract N2 - INTRODUCTION: ORCADES, a national prospective multicentre cohort study is evaluating the long-term benefits of a custom-made MRD in OSA patients noncompliant with Continuous Positive Airway Pressure (CPAP).AIMS AND METHODS: 379 OSA pts fitted with a custom-made titratable MRD (ResMed, Narval™) are evaluated over 5 years for evolution of respiratory and sleep data, symptoms, quality of life, compliance and side effects. Interim data of systematic polygraphy/polysomnography and dental sleep assessment at 2 years minimum FU are presented here.RESULTS: 73% of patients treated with MRD were kept in the study at 2 years FU. 16% stopped prematurely MRD for either side effect (8%) or lack of efficacy (8%), and 11% withdrew the study or returned to CPAP therapy. AHI decreased globally under MRD therapy from 28±14/h (median [Q1; Q3]: 26 [18; 37]) at baseline to 12±12/h (median [Q1; Q3]: 8 [4; 16]) at 2-year FU. An AHI<10 was achieved in 80%, 69% and 35% of patients with mild, moderate and severe OSA, respectively. Mean Epworth score was reduced from 12±5 to 7±4.In severe OSA patients (AHI>30), AHI was reduced from 41±11 (median [Q1; Q3]: 37 [32; 47]) at baseline to 18±15 (median [Q1; Q3]: 14 [8; 23]) at 2-year FU. Moreover, a decrease in baseline AHI by ≥50% + post-treatment AHI<20 was reached in 66% of severe OSA.Compared to previous 3 month-FU evaluation, MRD efficacy and compliance (6.7h/night, 6.6 days/week) were kept at similar level in the 3 OSA severity groups.CONCLUSION: Effectiveness of custom-made Narval MRD in noncompliant CPAP patients is satisfactorily maintained at long-term FU irrespective of initial OSA severity. ER -